Transformative nanoparticle platform for intracellular delivery of RNA
Location: United States
Employees: 1-10
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | IP Group N... | ipgroup-in... |
Mentions in press and media 2
| Date | Title | Description |
| 26.06.2026 | Hatch BioFund Invests In Optimeos Life Sciences To Advance Nanoparticle Drug Delivery Platform | Hatch BioFund announced an investment in Optimeos Life Sciences, a Princeton University spinout developing a proprietary nanoparticle platform for the intracellular delivery of therapeutic macromolecules, including RNA, DNA, and proteins. H... |
| 25.06.2026 | Optimeos Life Sciences Receives Investment From Hatch BioFund | Optimeos Life Sciences, Inc., a Princeton, NJ-based company developing a proprietary nanoparticle platform for the intracellular delivery of therapeutic macromolecules, including RNA, DNA and proteins, received an investment from Hatch BioF... |